Emergent Biosolutions (NYSE:EBS) Given New $10.00 Price Target at HC Wainwright

Key Points

• HC Wainwright cut Emergent Biosolutions’ price target to $10 from $12 while maintaining a “buy” rating, implying approximately 106% upside from the stock’s $4.85 price.
• Analyst sentiment is mixed: three analysts rate the stock Buy, one rates it Hold and one rates it Sell, resulting in a consensus “Hold” rating and a $10 consensus price target.
• Emergent reported quarterly earnings of $0.60 per share, beating the $0.08-per-share loss estimate, while revenue of $234.3 million exceeded the $177.5 million consensus forecast.

Emergent Biosolutions (NYSE:EBS - Get Free Report) had its price objective cut by stock analysts at HC Wainwright from $12.00 to $10.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price target would indicate a potential upside of 106.31% from the company's current price.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Emergent Biosolutions in a research report on Friday. Benchmark reiterated a "buy" rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, UBS Group restated a "buy" rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $10.00.

Emergent Biosolutions Trading Up 0.1%

Shares of Emergent Biosolutions stock opened at $4.85 on Monday. The stock has a fifty day moving average price of $7.82 and a 200-day moving average price of $8.75. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. Emergent Biosolutions has a 1 year low of $4.81 and a 1 year high of $14.06. The firm has a market cap of $250.09 million, a PE ratio of -1.37 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The company had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million.

Insider Buying and Selling

In other news, SVP Paul Anthony Williams sold 3,000 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares of the company's stock, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Emergent Biosolutions in the 2nd quarter worth about $39,525,000. Deutsche Bank AG purchased a new stake in Emergent Biosolutions during the 2nd quarter valued at approximately $1,592,000. Bank of New York Mellon Corp purchased a new position in Emergent Biosolutions during the second quarter valued at $1,841,000. State of Wyoming bought a new stake in shares of Emergent Biosolutions in the second quarter worth about $203,000. Finally, One Wealth Advisors LLC bought a new position in shares of Emergent Biosolutions during the 2nd quarter valued at approximately $139,000. Institutional investors own 78.40% of the company's stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source